أيسلندا -
الأيسلاندية -
LYFJASTOFNUN (Icelandic Medicines Agency)
pemetrexed w&h stofn fyrir innrennslisþykkni, lausn 500 mg
williams & halls ehf. - pemetrexedum dínatríum - stofn fyrir innrennslisþykkni, lausn - 500 mg
أيسلندا -
الأيسلاندية -
LYFJASTOFNUN (Icelandic Medicines Agency)
piperacillin/tazobactam wh innrennslisstofn, lausn 4 g/0,5 g
williams & halls ehf. - piperacillinum natríum; tazobactamum natríum - innrennslisstofn, lausn - 4 g/0,5 g
أيسلندا -
الأيسلاندية -
LYFJASTOFNUN (Icelandic Medicines Agency)
rivaroxaban wh (rivaroxavan pharos) filmuhúðuð tafla 15 mg
williams & halls ehf.* - rivaroxabanum inn - filmuhúðuð tafla - 15 mg
أيسلندا -
الأيسلاندية -
LYFJASTOFNUN (Icelandic Medicines Agency)
sertralin wh filmuhúðuð tafla 50 mg
williams & halls ehf - sertralinum hýdróklóríð - filmuhúðuð tafla - 50 mg
أيسلندا -
الأيسلاندية -
LYFJASTOFNUN (Icelandic Medicines Agency)
spectracillin filmuhúðuð tafla 875/125 mg
williams & halls ehf. - acidum clavulanicum kalíum; amoxicillinum tríhýdrat - filmuhúðuð tafla - 875/125 mg
أيسلندا -
الأيسلاندية -
LYFJASTOFNUN (Icelandic Medicines Agency)
soltamcin tafla með breyttan losunarhraða 6 mg/0,4 mg
williams & halls ehf. - solifenacinum súkkínat; tamsulosinum hýdróklóríð - tafla með breyttan losunarhraða - 6 mg/0,4 mg
الاتحاد الأوروبي -
الأيسلاندية -
EMA (European Medicines Agency)
ngenla
pfizer europe ma eeig - somatrogon - growth and development - sterum og undirstÚku hormÓn og hliÐstÆÐum - indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.
أيسلندا -
الأيسلاندية -
LYFJASTOFNUN (Icelandic Medicines Agency)
valpress comp filmuhúðuð tafla 160/12,5 mg
teva b.v.* - valsartanum inn; hydrochlorothiazidum inn - filmuhúðuð tafla - 160/12,5 mg
أيسلندا -
الأيسلاندية -
LYFJASTOFNUN (Icelandic Medicines Agency)
valpress comp filmuhúðuð tafla 80/12,5 mg
teva b.v.* - valsartanum inn; hydrochlorothiazidum inn - filmuhúðuð tafla - 80/12,5 mg
الاتحاد الأوروبي -
الأيسلاندية -
EMA (European Medicines Agency)
tybost
gilead sciences ireland uc - cobicistat - hiv sýkingar - veirueyðandi lyf til almennrar notkunar - tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (hiv-1) infected adults and adolescents aged 12 years and older:weighing at least 35 kg co‑administered with atazanavir orweighing at least 40 kg co‑administered with darunavir.